Advice
following an abbreviated submission:
micronised progesterone (Utrogestan®) is accepted for use within NHSScotland.
Indication under review: for adjunctive use with oestrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT).
Micronised progesterone provides an additional treatment choice in the therapeutic class of progestogens.
Download detailed advice729KB (PDF)
Medicine details
- Medicine name:
- micronised progesterone (Utrogestan)
- SMC ID:
- SMC2529
- Indication:
Adjunctive use with estrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT).
- Pharmaceutical company
- Besins Healthcare (UK) Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 December 2022